Searchable abstracts of presentations at key conferences in endocrinology

ea0042il6 | Hormone and Disease | Androgens2016

Androgens and cardiovascular diseases

Maggi Mario

Observational studies have consistently shown a relationship between low testosterone (T) and a higher cardiovascular (CV) risk profile. However, it is still obscure whether reduced T levels in the elderly play a direct pathogenetic role in the stratification of CV risk, or if CV diseases (CVD) and low T are concomitant conditions, both associated with the aging process. Much evidence supports both of these possibilities. In the meanwhile, recent reports in the scientific and ...

ea0056mte13 | (1) | ECE2018

Erectile dysfunction

Maggi Mario

Erectile dysfunction (ED) is a multidimensional disorder characterized by the inability to have successful intercourse with negative consequences in personal self-esteem and in couple relationship. Organic, relational and intrapsychic problems always concur in determining the erectile problem, although in different combination according to the patient characteristics, including age. Fifteen years ago, we have developed and validated a structured interview to identify and quant...

ea0063p1125 | Reproductive Endocrinology 2 | ECE2019

Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction

Rastrelli Giulia , Corona Giovanni , Maggi Mario

Background: Low testosterone (T) is frequent in men with chronical illnesses. The clinical features of T deficiency (TD) overlap with those of chronic diseases. The aim of this study is to evaluate the relative contribution of chronic disease score (CDS) and low T to the presence of TD symptoms.Methods: A consecutive series of 3862 men (aged 52.1±13.1 years) consulting for sexual dysfunction was studied. Several clinical and biochemical parameters w...

ea0035p286 | Clinical case reports Thyroid/Others | ECE2014

One month-Tadalafil 5 mg once daily administration improves clinical and ultrasound parameters of chronic pelvic pain syndrome/lower urinary tract symptoms

Lotti Francesco , Corona Giovanni , Maggi Mario

Introduction: Tadalafil 5 mg once daily (T5od) has been recently approved by the Food and Drug Administration for the treatment of lower urinary tract symptoms (LUTS), along with erectile dysfunction (ED). Recent pooled data analyses demonstrated that T5od–International Prostate Symptom Score related improvements were significant regardless of confounders. In addition, PDE5 inhibitors exert a positive effect on ejaculatory latency. We assessed the clinical outcome of 30 d...

ea0063p1126 | Reproductive Endocrinology 2 | ECE2019

Hormonal predictors of pathologic findings at magnetic resonance imaging in secondary hypogonadal men

Cipriani Sarah , Corona Giovanni , Maggi Mario , Rastrelli Giulia

Introduction: Secondary hypogonadism (sHG) is the most common form of hypogonadism. sHG can arise from any dysregulation of hypothalamic-pituitary (HP) axis due to functional or organic disorders. HP organic disorders are often diagnosed using pituitary magnetic resonance imaging (MRI). However, MRI is an expensive and not widespread exam and it cannot be routinely offered to all sHG patient. The Endocrine Society guidelines suggest MRI scan in sHG men with total testosterone ...

ea0035p179 | Cardiovascular Endocrinology & Lipid Metabolism | ECE2014

Characteristics of compensated hypogonadism in patients with sexual dysfunction

Corona Giovanni , Maseroli Elisa , Rastrelli Giulia , Maggi Mario

Introduction: In the last few years the view that subclinical endocrine disorders represent milder forms of the clinically overt disease has emerged. Accordingly, it has been proposed that compensated hypogonadism represents a genuine clinical subgroup of individuals with late onset hypogonadism (LOH). The aim of the present study is to investigate the association of compensated hypogonadism with clinical and psychological characteristics of male subjects complaining for sexua...

ea0035p201 | Cardiovascular Endocrinology & Lipid Metabolism | ECE2014

Low testosterone syndrome protects from major adverse cardiovascular events in subjects at high cardiovascular burden

Corona Giovanni , Ratrelli Giulia , Maseroli Elisa , Forti Gianni , Maggi Mario

Introduction: The role of testosterone in cardiovascular (CV) health of men is controversial. Several data suggest that hypogonadism is associated with CV mortality but not morbidity. However, recent evidence shows that hypogonadal subjects treated with testosterone replacement therapy have a higher incidence of major adverse CV events (MACE). The aim of this study is to analyse whether the gonadal status might predict MACE incidence according to the previous history of MACE, ...

ea0032p657 | Male reproduction | ECE2013

Impaired masturbation induced erections: a new cardiovascular risk factor for male subjects with sexual dysfunction

Rastrelli Giulia , Boddi Valentina , Corona Giovanni , Forti Gianni , Maggi Mario

Introduction: Erectile dysfunction (ED) is considered an early surrogate marker of silent, or even overt, cardiovascular diseases (CVD). However, epidemiological studies take into account only sexual intercourse-related erections. Although autoeroticism is a very common practice, data on masturbation-induced erections as a possible predictor of major adverse cardiovascular events (MACE) are lacking.Aim: To evaluate the clinical correlates of impaired mas...

ea0049gp147 | Male Reproduction and Endocrine Disruptors | ECE2017

Effects of physical exercise or metformin on testosterone deficiency and erectile dysfunction associated to metabolic syndrome

Vignozzi Linda , Filippi Sandra , Comeglio Paolo , Cellai Ilaria , Corcetto Francesca , Corno Chiara , Maggi Mario

Metabolic Syndrome (MetS) is a cluster of clinical conditions, associated to an increased cardiovascular and metabolic risk, to hypogonadism and erectile dysfunction (ED). Lifestyle modification (including physical exercise, PhyEx) and metformin (MET) are well-known treatments for the condition. We established an animal model of MetS that recapitulates the human phenotype, including andrologic derangements.The aim of this study was to investigate in expe...

ea0049ep377 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2017

The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis and visceral adipose tissue dysfunction in a rabbit model of high fat diet-induced metabolic syndrome

Comeglio Paolo , Cellai Ilaria , Filippi Sandra , Morelli Annamaria , Sarchielli Erica , Adorini Luciano , Maggi Mario , Vignozzi Linda

The nuclear Farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor 1 (TGR5) are bile acids receptors that play a key role in energy metabolism. In an animal model of non-genomic metabolic syndrome (MetS), obtained with a high fat diet (HFD), treatment with the dual FXR/TGR5 agonist INT767 reduced visceral adipose tissue (VAT) accumulation, insulin resistance, hypercholesterolemia and nonalcoholic steatohepatitis (NASH). In liver, INT767 reduced the high macrop...